Skip to main navigation Skip to search Skip to main content

Banff 2022 Kidney Commentary: Reflections and Future Directions

  • Marion Rabant*
  • , Benjamin A Adam
  • , Olivier Aubert
  • , Georg A Böhmig
  • , Marian Clahsen Van-Groningen
  • , Lynn D Cornell
  • , Aiko P J de Vries
  • , Edmund Huang
  • , Nicolas Kozakowski
  • , Agnieszka Perkowska-Ptasinska
  • , Leonardo V Riella
  • , Ivy A Rosales
  • , Carrie Schinstock
  • , Naomi Simmonds
  • , Olivier Thaunat
  • , Michelle Willicombe
  • *Corresponding author for this work
  • Hôpital Universitaire Necker-Enfants Malades
  • University of Alberta
  • Medical University of Vienna
  • RWTH Aachen University
  • Department of Laboratory Medicine and Pathology
  • Leiden University Medical Centre
  • Cedars-Sinai Medical Center
  • Medical University of Warsaw
  • Harvard Medical School
  • Mayo Clinic Rochester, MN
  • Department of Pathology
  • Hospital Edouard Herriot
  • Imperial College Healthcare NHS Trust

Research output: Contribution to journalReview articleAcademicpeer-review

7 Citations (Scopus)
81 Downloads (Pure)

Abstract

In September 2022, in Banff, Alberta, Canada, the XVIth Banff meeting, corresponding to the 30th anniversary of the Banff classification, was held, leading to 2 recent publications. Discussions at the Banff meeting focused on proposing improvements to the Banff process as a whole. In line with this, a unique opportunity was offered to a selected group of 16 representatives from the pathology and transplant nephrology community, experts in the field of kidney transplantation, to review these 2 Banff manuscripts. The aim was to provide an insightful commentary, to gauge any prospective influence the proposed changes may have, and to identify any potential areas for future enhancement within the Banff classification. The group expressed its satisfaction with the incorporation of 2 new entities, namely "microvascular inflammation/injury donor-specific antibodies-negative and C4d negative" and "probable antibody-mediated rejection," into category 2. These changes expand the classification, facilitating the capture of more biopsies and providing an opportunity to explore the clinical implications of these lesions further. However, we found that the Banff classification remains complex, potentially hindering its widespread utilization, even if a degree of complexity may be unavoidable given the intricate pathophysiology of kidney allograft pathology. Addressing the histomorphologic diagnosis of chronic active T cell-mediated rejection (CA TCMR), potentially reconsidering a diagnostic-agnostic approach, as for category 2, to inflammation in interstitial fibrosis and tubular atrophy and chronic active T cell-mediated rejection was also an important objective. Furthermore, we felt a need for more evidence before molecular diagnostics could be routinely integrated and emphasized the need for clinical and histologic context determination and the substantiation of its clinical impact through rigorous clinical trials. Finally, our discussions stressed the ongoing necessity for multidisciplinary decision-making regarding patient care.

Original languageEnglish
Pages (from-to)292-299
Number of pages8
JournalTransplantation
Volume109
Issue number2
DOIs
Publication statusPublished - 1 Feb 2025

Bibliographical note

Publisher Copyright:
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Fingerprint

Dive into the research topics of 'Banff 2022 Kidney Commentary: Reflections and Future Directions'. Together they form a unique fingerprint.

Cite this